Akebia Therapeutics Statistics
Total Valuation
AKBA has a market cap or net worth of $252.14 million. The enterprise value is $295.78 million.
| Market Cap | 252.14M |
| Enterprise Value | 295.78M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AKBA has 277.11 million shares outstanding. The number of shares has increased by 15.07% in one year.
| Current Share Class | 277.11M |
| Shares Outstanding | 277.11M |
| Shares Change (YoY) | +15.07% |
| Shares Change (QoQ) | +0.96% |
| Owned by Insiders (%) | 2.25% |
| Owned by Institutions (%) | 39.32% |
| Float | 270.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.15 |
| Forward PS | 1.46 |
| PB Ratio | 9.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 6.26 |
| P/OCF Ratio | 6.07 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 7.35 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 7.96.
| Current Ratio | 1.43 |
| Quick Ratio | 1.30 |
| Debt / Equity | 7.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | 4.95 |
| Interest Coverage | -0.87 |
Financial Efficiency
Return on equity (ROE) is -109.38% and return on invested capital (ROIC) is -1.63%.
| Return on Equity (ROE) | -109.38% |
| Return on Assets (ROA) | -1.06% |
| Return on Invested Capital (ROIC) | -1.63% |
| Return on Capital Employed (ROCE) | -8.01% |
| Weighted Average Cost of Capital (WACC) | 6.13% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | -$152,918 |
| Employee Count | 194 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.74 |
Taxes
In the past 12 months, AKBA has paid $1.82 million in taxes.
| Income Tax | 1.82M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.96% in the last 52 weeks. The beta is 0.24, so AKBA's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -75.96% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 27.43 |
| Average Volume (20 Days) | 3,533,964 |
Short Selling Information
The latest short interest is 19.08 million, so 6.88% of the outstanding shares have been sold short.
| Short Interest | 19.08M |
| Short Previous Month | 19.18M |
| Short % of Shares Out | 6.88% |
| Short % of Float | 7.06% |
| Short Ratio (days to cover) | 3.26 |
Income Statement
In the last 12 months, AKBA had revenue of $219.06 million and -$29.67 million in losses. Loss per share was -$0.11.
| Revenue | 219.06M |
| Gross Profit | 178.37M |
| Operating Income | -5.88M |
| Pretax Income | -27.85M |
| Net Income | -29.67M |
| EBITDA | -13.57M |
| EBIT | -15.13M |
| Loss Per Share | -$0.11 |
Balance Sheet
The company has $155.55 million in cash and $199.19 million in debt, with a net cash position of -$43.64 million or -$0.16 per share.
| Cash & Cash Equivalents | 155.55M |
| Total Debt | 199.19M |
| Net Cash | -43.64M |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 25.02M |
| Book Value Per Share | 0.09 |
| Working Capital | 68.69M |
Cash Flow
In the last 12 months, operating cash flow was $41.55 million and capital expenditures -$1.29 million, giving a free cash flow of $40.26 million.
| Operating Cash Flow | 41.55M |
| Capital Expenditures | -1.29M |
| Depreciation & Amortization | 1.55M |
| Net Borrowing | -5.85M |
| Free Cash Flow | 40.26M |
| FCF Per Share | $0.15 |
Margins
Gross margin is 81.43%, with operating and profit margins of -2.68% and -13.54%.
| Gross Margin | 81.43% |
| Operating Margin | -2.68% |
| Pretax Margin | -12.71% |
| Profit Margin | -13.54% |
| EBITDA Margin | -6.20% |
| EBIT Margin | -6.90% |
| FCF Margin | 18.38% |
Dividends & Yields
AKBA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.07% |
| Shareholder Yield | -15.07% |
| Earnings Yield | -11.77% |
| FCF Yield | 15.97% |
Analyst Forecast
The average price target for AKBA is $3.80, which is 394.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.80 |
| Price Target Difference | 394.56% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -8.59% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AKBA has an Altman Z-Score of -5.02 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.02 |
| Piotroski F-Score | 3 |